Evidence map›Paper›PMID 22402071›Full record

ArticleJournal of the American College of Cardiology2012

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

Sameer Ather, Wenyaw Chan, Biykem Bozkurt, David Aguilar, Kumudha Ramasubbu, Amit A Zachariah, Xander H T Wehrens, Anita Deswal

2 registry-linked trialsAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American College of Cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 321 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
321citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04189029 unknown statusnot on this mapstarted 2019, after this paper: background citation

Redefining the Phenotypic Spectrum of Heart Failure With Preserved Ejection Fraction (HFpEF) by Deep Phenotyping and Machine Learning Methods: The PACIFIC-PRESERVED Study (PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF Study)

Typeobservational_patient_registrySponsorAssistance Publique - Hôpitaux de ParisRan2019 to 2025Enrolled175ConditionsHeart Failure, Heart Failure With Preserved Ejection FractionArmsExtensive phenotyping
NCT06130059 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Pilot Study to Evaluate the Efficacy of Low Dose Colchicine (LoDoCo ®) to Improve Exercise Capacity Among Patients With Chronic Stable HFpEF and Systemic Inflammation

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2024 to 2027Enrolled60ConditionsHeart Failure, InflammationArmsLow Dose Colchicine, Placebo
3 · Its place in the literature

Who cites it

321 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Automatic positive airway pressure for obstructive sleep apnea in heart failure with reduced ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2021
    Trial
  13. Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial.The British journal of general practice : the journal of the Royal College of General Practitioners · 2021
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Article

261 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Sameer AtherBaylor College of Medicine, Houston, Texas, USA.
Wenyaw Chan
Biykem Bozkurt
David Aguilar
Kumudha Ramasubbu
Amit A Zachariah
Xander H T Wehrens
Anita Deswal

Funding

Ryanodine receptor regulation in post-operative atrial fibrillationR01HL089598 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI WEHRENS, XANDER H.T. · 2007 to 2022
$6.5M
Regulation of Sarcoplasmic Reticulum Calcium Release in Heart FailureR01HL091947 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI WEHRENS, XANDER H.T. · 2009 to 2019
$3.2M
Determining the Role of Junctophilin-2 in Cardiac DiseaseR01HL117641 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI WEHRENS, XANDER H.T. · 2014 to 2017
$2.3M
The Texas Medical Center Regional Coordinating Center for Heart FailureU01HL084890 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI DESWAL, ANITA · 2006 to 2011
$1.8M
Development of novel compounds for the treatment of atrial fibrillationR41HL129570 · NHLBI · ELEX BIOTECH, LLC · PI WEHRENS, XANDER H.T. · 2015 to 2015
$428k
NHLBI NIH HHS R01 HL089598NHLBI NIH HHS R01 HL091947NHLBI NIH HHS R01 HL117641NHLBI NIH HHS R41 HL129570NHLBI NIH HHS U01 HL084890
6 · The paper itself

Abstract

objectivesThe aim of this study was to evaluate the prevalence and prognostic impacts of noncardiac comorbidities in patients with heart failure (HF) with preserved ejection fraction (HFpEF) compared with those with HF with reduced ejection fraction (HFrEF).

backgroundThere is a paucity of information on the comparative prognostic significance of comorbidities between patients with HFpEF and those with HFrEF.

methodsIn a national ambulatory cohort of veterans with HF, the comorbidity burden of 15 noncardiac comorbidities and the impacts of these comorbidities on hospitalization and mortality were compared between patients with HFpEF and those with HFrEF.

resultsThe cohort consisted of 2,843 patients with HFpEF and 6,599 with HFrEF with 2-year follow-up. Compared with patients with HFrEF, those with HFpEF were older and had higher prevalence of chronic obstructive pulmonary disease, diabetes, hypertension, psychiatric disorders, anemia, obesity, peptic ulcer disease, and cancer but a lower prevalence of chronic kidney disease. Patients with HFpEF had lower HF hospitalization, higher non-HF hospitalization, and similar overall hospitalization compared with those with HFrEF (p < 0.001, p < 0.001, and p = 0.19, respectively). An Increasing number of noncardiac comorbidities was associated with a higher risk for all-cause admissions (p < 0.001). Comorbidities had similar impacts on mortality in patients with HFpEF compared with those with HFrEF, except for chronic obstructive pulmonary disease, which was associated with a higher hazard (1.62 [95% confidence interval: 1.36 to 1.92] vs. 1.23 [95% confidence interval: 1.11 to 1.37], respectively, p = 0.01 for interaction) in patients with HFpEF.

conclusionsThere is a higher noncardiac comorbidity burden associated with higher non-HF hospitalizations in patients with HFpEF compared with those with HFrEF. However, individually, most comorbidities have similar impacts on mortality in both groups. Aggressive management of comorbidities may have an overall greater prognostic impact in HFpEF compared to HFrEF.

Indexed as

ComorbidityStroke VolumeAgedAged, 80 and overFemaleHeart FailureHumansMaleMiddle AgedPrevalenceRetrospective StudiesUnited States

Identifiers

PMID22402071
PMCPMC4687406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.